



CASE RG/G-33302P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 485-023 915 US
Express Mail Label Number

May 19, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1623

NANDI ET AL.

Examiner: Michael C. Henry

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR
PREPARING

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 24, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945

Date: May 19, 2005



CASE RG/G-33302P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 485022915 US
Express Mail Label Number

May 19, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1623

NANDI ET AL.

Examiner: Michael C. Henry

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR
PREPARING

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.


Respectfully submitted,


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945
Date: May 19, 2005

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
RG/G-33302P1
APPLICATION NO.
10/631,874
APPLICANT
NANDI ET AL.
FILING DATE
JULY 31, 2003

Group
1623**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	09 315971	12/9/97	JP (Abstract)			<input type="checkbox"/>	<input type="checkbox"/>
AN	1 054 019	11/22/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
AO	00/38650	7/6/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
AP	03/041683	5/22/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Database WPI, Section Ch, Week 199808, Derwent Publications, Ltd., London, GB; Class A96, AN 1998-082557 XP002305733 and JP 09 315971 (1997).
AS	Graul et al., "Fexofenadine Hydrochloride Antihistaminic Terfenadine Carboxylate Hydrochloride MDL-16455A Allegra™", Drugs of the Future, Vol. 21, No. 10, pp. 1017-1021 (1996).
AT	Patent Abstracts of Japan, Vol. 1998, No. 12 and JP 10 194969 (1998).
AU	Database WPI, Section Ch, Week 198623, Derwent Publications Ltd., London, GB; Class B03, AN 1986-147747 XP 002305734 and JP 61 083123 (1986).

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.